Slatinska, Janka <br/><br/>
Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study.  [electronic resource] 

 -  HLA  12 2018 
 - 47-50 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2059-2310 
<br/><br/><label>Standard No.: </label>10.1111/tan.13387  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenal Cortex Hormones--therapeutic use<br/>Adult<br/>Bortezomib--therapeutic use<br/>Drug Administration Schedule<br/>Female<br/>Graft Rejection--blood<br/>Graft Survival<br/>HLA Antigens--genetics<br/>Histocompatibility Testing--methods<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Isoantibodies--blood<br/>Kidney Transplantation<br/>Male<br/>Middle Aged<br/>Patient Safety<br/>Pilot Projects<br/>Plasmapheresis--methods<br/>Prognosis<br/>Rituximab--therapeutic use<br/>Tissue Donors<br/>Transplantation, Homologous<br/>Treatment Outcome